Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fluvoxamine
Drug ID BADD_D00950
Description Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Indications and Usage Indicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) [FDA Label]. Has also been used in the management of bulimia nervosa [A250].
Marketing Status approved; investigational
ATC Code N06AB08
DrugBank ID DB00176
KEGG ID D07984
MeSH ID D016666
PubChem ID 5324346
TTD Drug ID D03HFG
NDC Product Code Not Available
UNII O4L1XPO44W
Synonyms Fluvoxamine | Fluvoxadura | Fluvoxamin AL | Fluvoxamin beta | Fluvoxamin Stada | Fluvoxamin-neuraxpharm | Fluvoxamin neuraxpharm | Fluvoxamin-ratiopharm | Fluvoxamin ratiopharm | ratio-Fluvoxamine | ratio Fluvoxamine | Fluvoxamina Geminis | Geminis, Fluvoxamina | Fluvoxamine Maleate | Fluvoxamine Maleate, (E)-Isomer | Fluvoxamine, (Z)-Isomer | Luvox | Floxyfral | Fevarin | Dumirox | Faverin | Novo-Fluvoxamine | Novo Fluvoxamine | Nu-Fluvoxamine | Nu Fluvoxamine | PMS-Fluvoxamine | PMS Fluvoxamine | Desiflu | DU-23000 | DU 23000 | DU23000
Chemical Information
Molecular Formula C15H21F3N2O2
CAS Registry Number 54739-18-3
SMILES COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vasculitis10.02.02.006; 24.12.04.027--
Ventricular tachycardia02.03.04.010--
Vertigo04.04.01.003; 17.02.12.002--
Viral infection11.05.04.001--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.0030.002061%
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
White blood cell count decreased13.01.06.012--
Withdrawal syndrome19.07.06.023; 08.06.02.012--Not Available
Yawning22.12.03.037--Not Available
Homicidal ideation19.05.01.008--Not Available
Self-injurious ideation19.12.01.007--Not Available
Madarosis23.02.02.004; 06.06.04.010--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.001--Not Available
Depressive symptom19.15.02.003--Not Available
Affect lability19.04.01.001--Not Available
Haemorrhage24.07.01.002--Not Available
Obsessive rumination19.06.05.006--Not Available
Rectal tenesmus15.05.03.011; 07.03.03.001--Not Available
Female sexual dysfunction19.08.05.001; 21.03.02.004--Not Available
Major depression19.15.01.003--Not Available
Heart alternation02.03.02.023--Not Available
Nuchal rigidity17.05.02.006; 15.05.04.005--Not Available
The 13th Page    First    Pre   13 14 15    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene